- Home
- GUT vs ALMS Comparison
GUT vs ALMS Comparison
Compare GUT & ALMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUT
- ALMS
- Stock Information
- Founded
- GUT 1999
- ALMS 2021
- Country
- GUT United States
- ALMS United States
- Employees
- GUT N/A
- ALMS N/A
- Industry
- GUT Trusts Except Educational Religious and Charitable
- ALMS
- Sector
- GUT Finance
- ALMS
- Exchange
- GUT Nasdaq
- ALMS NYSE
- Market Cap
- GUT 475.6M
- ALMS 402.6M
- IPO Year
- GUT N/A
- ALMS 2024
- Fundamental
- Price
- GUT $5.65
- ALMS $2.86
- Analyst Decision
- GUT
- ALMS Strong Buy
- Analyst Count
- GUT 0
- ALMS 7
- Target Price
- GUT N/A
- ALMS $24.50
- AVG Volume (30 Days)
- GUT 176.3K
- ALMS 1.1M
- Earning Date
- GUT 01-01-0001
- ALMS 08-12-2025
- Dividend Yield
- GUT 10.93%
- ALMS N/A
- EPS Growth
- GUT N/A
- ALMS N/A
- EPS
- GUT N/A
- ALMS N/A
- Revenue
- GUT N/A
- ALMS $17,389,000.00
- Revenue This Year
- GUT N/A
- ALMS N/A
- Revenue Next Year
- GUT N/A
- ALMS N/A
- P/E Ratio
- GUT N/A
- ALMS N/A
- Revenue Growth
- GUT N/A
- ALMS N/A
- 52 Week Low
- GUT $4.60
- ALMS $2.81
- 52 Week High
- GUT $7.38
- ALMS $13.53
- Technical
- Relative Strength Index (RSI)
- GUT 61.69
- ALMS N/A
- Support Level
- GUT $5.52
- ALMS N/A
- Resistance Level
- GUT $5.78
- ALMS N/A
- Average True Range (ATR)
- GUT 0.07
- ALMS 0.00
- MACD
- GUT -0.00
- ALMS 0.00
- Stochastic Oscillator
- GUT 58.06
- ALMS 0.00
About GUT Gabelli Utility Trust (The)
Gabelli Utility Trust operates as a diversified closed-end investment management company. The fund's primary objective is the long-term growth of capital and income. To achieve its objective, the fund may invest its assets in common stocks and other securities of foreign and domestic companies involved in providing products, services, or equipment for the generation or distribution of electricity, gas, & water; and telecommunications services or infrastructure operations. It invests in various sectors, of which Electric Integrated, Water, Telecommunications, and U.S. Government Obligations and others.
About ALMS ALUMIS INC
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.